---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-024081"
form_type: "8-K"
ticker: "CPHI"
cik: "0001106644"
company_name: "CHINA PHARMA HOLDINGS, INC."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T09:57:39.888494+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# China Pharma regains NYSE American price compliance but remains under equity plan with delisting risk

## Summary
- Resolved low selling price deficiency via 1-for-10 reverse stock split on March 6, 2023.
- Still non-compliant with stockholders' equity standards (Sections 1003(a)(ii) and (iii)).
- Must achieve full compliance by December 15, 2023 or face delisting proceedings.
- ".BC" indicator remains on ticker CPHI.
- If average share price falls below $0.20 over 30 days, immediate review.

## SEC filing metadata
- accession: 0001213900-23-024081
- form_type: 8-K
- ticker: CPHI
- cik: 0001106644
- company_name: CHINA PHARMA HOLDINGS, INC.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024081/0001213900-23-024081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106644/000121390023024081/ea175993-8k_chinapharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-024081
- JSON: https://secwatch.observer/filing/0001213900-23-024081.json
- Plain text: https://secwatch.observer/filing/0001213900-23-024081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.